

Int'l Appl. No. : PCT/GB98/01627

Int'l Filing Date : June 4, 1998

On page 58, line 2, after the sequence "gcgc AAG CTT gaa atc aaa egg GCC TCC ACA CAG AGC CCA" please insert --(SEQ ID NO:19)--.

On page 58, line 6, after the sequence "gcgc ctcgag TCA TTT ACC GGG ATT TAC AGA" please insert --(SEQ ID NO:20)--.

On page 59, line 7, after the sequence "GG ACT AGT AAT AGT GAC TCT GAA TGT CCC" please insert --(SEQ ID NO:21)--.

On page 59, line 11, after the sequence "ATT AGC GGC CGC TTA GCG CAG TTC CCA CCA CTT C" please insert --(SEQ ID NO:22)--.

On page 66, line 1, please cancel the word "CLAIMS" and substitute in its place --WHAT IS CLAIMED IS:--.

IN THE CLAIMS:

Cancel Claims 22, 23, 26, 30, 35, 39, and 44.

Amend the remaining claims as follows:

1. (Amended) A vector comprising a polynucleotide [sequence ("NS")] encoding [for] a [tumour]tumor-interacting protein [("TIP")] and optionally comprising a nucleotide sequence of interest ("NOI") which NOI encodes a product of interest ("POI"); wherein the [TIP]tumor-interacting protein is capable of recognizing a [tumour]tumor, [such that in use] and wherein the vector is capable of delivering [the NOI] a second polynucleotide of interest [and/or the POI] to the [tumour]tumor.

2. (Amended) [A]The vector according to claim 1 wherein the vector comprises the [NOI] second polynucleotide of interest.

3. (Amended) [A]The vector according to claim 2 wherein the [NOI] second polynucleotide of interest is [a] therapeutic [NOI and/or the POI is a therapeutic [POI] product of interest].

4. (Amended) [A]The vector according to [any one of the preceding claims]Claim 1 wherein [in use] the vector is capable of delivering the [NOI] second polynucleotide of interest [and/or the POI] to the interior of a [tumour]tumor mass.

5. (Amended) [A]The vector according to [any one of the preceding claims]Claim 1 wherein the [TIP]tumor-interacting protein [is or] comprises a [tumour]tumor-binding protein [("TBP")].